Research has revealed what we already suspected—randomized controlled trials are lacking in the field of bladder cancer. Many areas require further investigation, and we must try to incentivize clinicians to perform the much-needed trials. A newly established patient advocacy group will be invaluable in this endeavour.
This is a preview of subscription content, log in via an institution to check access.
References
Bachir, B. G. et al. Demographic analysis of randomized controlled trials in bladder cancer. BJU Int. http://dx.doi.org/10.1111/j.1464-410X.2012.11401.x.
Jemal, A. et al. Cancer Statistics, 2008. CA Cancer J. Clin. 58, 71–96 (2008).
Ries, L. A. G. et al. SEER Cancer Statistics Review, 1975–2004 [online], (2007).
Heney, N. M. et al. Superficial bladder cancer: progression and recurrence. J. Urol. 130, 1083–1086 (1983).
Lotan, Y. et al. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer 115, 4096–4103 (2009).
Soloway, M. S., Bruck, D. S. & Kim, S. S. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J. Urol. 170, 438–441 (2003).
Herr, H. W. Does cystoscopy correlate with the histology of recurrent papillary tumours of the bladder? BJU Int. 88, 683–685 (2001).
Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 54, 303–314 (2008).
Schmitz-Drager, B. J. et al. in Bladder Cancer 2nd Edn (eds Soloway, M. & Khoury, S.) 171–205 (European Association of Urology, Paris, 2012).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares he has acted as a consultant and received grant/research support (inc. clinical trials) from Allergan, Photocure and Sanofi-Aventis.
Rights and permissions
About this article
Cite this article
Soloway, M. Lack of progress in bladder cancer—what are the obstacles?. Nat Rev Urol 10, 5–6 (2013). https://doi.org/10.1038/nrurol.2012.219
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2012.219
- Springer Nature Limited
This article is cited by
-
Promoting effect and immunologic role of secretogranin II on bladder cancer progression via regulating MAPK and NF-κB pathways
Apoptosis (2024)
-
Peptidase inhibitor (PI16) impairs bladder cancer metastasis by inhibiting NF-κB activation via disrupting multiple-site ubiquitination of NEMO
Cellular & Molecular Biology Letters (2023)
-
Repression of the PRELP gene is relieved by histone deacetylase inhibitors through acetylation of histone H2B lysine 5 in bladder cancer
Clinical Epigenetics (2022)
-
circDHTKD1 promotes lymphatic metastasis of bladder cancer by upregulating CXCL5
Cell Death Discovery (2022)
-
A positive feedback loop between TAZ and miR-942-3p modulates proliferation, angiogenesis, epithelial-mesenchymal transition process, glycometabolism and ROS homeostasis in human bladder cancer
Journal of Experimental & Clinical Cancer Research (2021)